Epirium Bio is a startup based in the United States, most recent round Series A, 1 tracked investor.
Based in the United States, Epirium Bio is a startup. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Epirium Bio is a biopharmaceutical company developing orally bioavailable small molecule therapies targeting PGE-2 signaling to treat neuromuscular, inflammatory, and fibrotic diseases, with a lead compound in Phase 2b for sarcopenia.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.